Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.
Clinical trials during COVID-19.
Bringing the clinical trial to the patient with innovation and in-home solutions.
ICON provides its full range of clinical, consulting and commercial services across several sectors.
A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
Developing transformative therapies requires a flexible approach.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.
With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
Harmonising data and services for more integrated decentralised clinical trials.
BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.
Establishing a platform for improvement
Patient focused research for better outcomes.
ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.
19 - 23 June 2022 - ICON's Jacqui Whiteway and Jane Galinsky will be speaking at this conference.
23 June 2022 - Register today
Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.
ICON is committed to making a positive impact on our people, environment and our community.
Partners Making a Difference.
59:19
With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.
1:02:03
59:59
32:11
58:34
